In CRC, patients who have microsatellite instability-High (MSI-H) and mismatch repair defection (dMMR) in tumor genetic phenotypes have more positive responses to PD1/PDL1 inhibitor immune treatment [9, 10]. Here, PDCD1 is linked to neoplasm.